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Abstract
Somatic mutations in the RAS genes are frequent in human tumors, especially in pancreatic, colorectal, and non-small-cell lung
cancers. Such mutations generally decrease the ability of Ras to hydrolyze GTP, maintaining the protein in a constitutively active
GTP-bound form that drives uncontrolled cell proliferation. Efforts to develop drugs that target Ras oncoproteins have been
unsuccessful. Recent emerging data suggest that Ras regulation is more complex than the scientific community has believed for
decades. In this review, we summarize advances in the “textbook” view of Ras activation. We also discuss a novel type of Ras
regulation that involves direct phosphorylation and dephosphorylation of Ras tyrosine residues. The discovery that pharmaco-
logical inhibition of the tyrosine phosphoprotein phosphatase SHP2maintains mutant Ras in an inactive state suggests that SHP2
could be a novel drug target for the treatment of Ras-driven human cancers.
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1 Introduction
The products of the RAS family of proto-oncogenes are low-
molecular-weight guanine nucleotide-binding proteins that
mediate cell growth, survival, and differentiation via interac-
tions with a variety of effector proteins [1, 2]. Ras proteins are
enzymes capable of hydrolyzing bound GTP to GDP and
inorganic phosphate. Cycling between GDP-bound inactive
and GTP-bound active forms is facilitated by guanine nucle-
otide exchange factors (GEF) and GTPase-activating proteins
(GAPs) via a mechanism that is common in the Ras superfam-
ily [3, 4]. The three human RAS genes encode four highly
similar proteins: H-Ras, N-Ras, and K-Ras4A and K-Ras4B.
The expression of two protein products from the mammalian
K-RAS gene results from the use of alternative fourth exons.
Single-base substitutions in codons 12, 13, or 61 ofRAS are
among the most frequent oncogenic mutations in human can-
cers [5]. These mutations activate Ras by eliminating its GTP
hydrolysis activity. Despite the high degree of similarity be-
tween the isoforms, K-Ras is the most frequently mutated;
indeed, K-Ras mutations have been identified in 22% of all
tumors investigated (compared with 8% for N-Ras and 3% for
H-Ras) [6, 7].
1.1 Conventional regulation of Ras activation
The first conceptualization of Ras activation was established
in the early 1990s. According to this early model, growth
factors, e.g., epidermal growth factor (EGF), induce a rapid
dimerization and autophosphorylation of their receptors at the
plasma membrane. Phosphotyrosine residues in the non-
catalytic region of the receptors bind a variety of signaling
molecules possessing SH2 or PTB domains, including the
Grb2 adaptor protein. Grb2 is a small ubiquitously expressed
and highly conserved protein with a central SH2 domain
flanked by two SH3 domains. Binding of Grb2 to activated
receptors via its SH2 domain recruits the SOS-Grb2 complex
from the cytosol, placing SOS in proximity to the plasma
membrane where it can stimulate the exchange of GDP for
GTP on membrane-bound Ras. These early studies suggested
that SOS translocation to the plasma membrane was sufficient
for Ras activation [8–10].
However, the importance of Grb2-mediated membrane
recruitment of SOS was challenged by several critical ques-
tions emerging from subsequent studies. For example, a
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transforming mutant of SOS1 that was unable to bind Grb2
seemed to mediate normal downstream signaling [11].
Another study suggested that Grb2 negatively modulates
SOS activity under basal conditions [12]. In addition, SOS
constructs lacking the Grb2-binding proline-rich regions
were found to be successfully recruited to Ras-enriched
membranes [13]. How can one explain SOS activation at
the plasma membrane if Grb2’s activity is limited at the
membrane? The solution may come from the multidomain
structure of SOS, which affords it multiple functions, i.e.,
catalysis, membrane binding (protein-protein and protein-
lipid interactions), allosteric regulation, and autoinhibition.
SOS possesses a histone-fold domain, Dbl homology (DH)
and Pleckstrin homology (PH) domains, a Ras exchanger
motif (REM), the catalytic cell division cycle 25 (Cdc25)
domain, and a proline-rich C-terminal region that binds
Grb2 [10]. Two of the abovementioned domains exert
autoinhibitory effects on SOS. The proline-rich region of
SOS binds the SH3 domains of Grb2, facilitating SOS re-
cruitment to the plasma membrane. On the other hand, this
interaction overcomes negative regulation of SOSby its own
C-terminus. Similarly, contact between the SOS PH domain
and negatively charged phospholipids also induces confor-
mational changes that allow binding of allosteric Ras to the
REMdomain, which results in processive catalysis of nucle-
otide exchange on the substrate Ras in the Cdc25 domain
[14–16] (Fig. 1).
Biologically active Ras is strictly localized to membranes
determined by specific lipid modifications [17]; therefore, it
is not surprising that SOS, upon activation in tyrosine sig-
naling pathway, also binds to membranes containing allo-
steric and substrate Ras. Furthermore, it has also been
shown that constitutive membrane localization of SOS ac-
tivates Ras [18]. A recent series of elegant experiments from
the laboratory of Jay T. Groves shed new light on the dy-
namics of SOS activation. Via single-molecule assays, they
identified distinct activation states of SOS, reflecting differ-
ent stable configurations of the protein complex itself [19].
More interestingly, they recognized a subgroup of SOS
molecules in which Ras GTP bound to the SOS allosteric
site had a smaller activating effect compared with that of
bound Ras-GDP [19]. It seems well-established that SOS
translocation to the plasma membrane requires a number
of protein-lipid and protein-protein interactions, as de-
scribed above; however, it has long remained unclear how
SOS activity is downregulated in tyrosine kinase signaling.
Via expression of EGFP-tagged SOS in B cells, they re-
vealed that activated and membrane-translocated SOS re-
mains in the membrane for more than 10 min. By half an
hour after stimulation, most SOS protein seemed to appear
in perinuclear vesicular structures, suggesting that SOS is
incapable of dissociating from the membrane, instead being
subjected to endocytosis [13] (Fig. 1).
1.2 Ras inhibition by direct tyrosine phosphorylation
In the first report on Ras phosphorylation in 1989 [20], the
authors reported that purified H-Ras was phosphorylated
in vitro by insulin receptor in the presence of poly(L-lysine).
Interestingly, poly(L-lysine) was not necessary for K-Ras
phosphorylation in the same assay system, perhaps due to
the unique, extremely basic hypervariable region of K-Ras,
which might effectively substitute for the poly(L-lysine).
Abl tyrosine kinase was also reported to phosphorylate H-
Ras on tyrosine residue 137 [21]. Tyrosine phosphorylation
of H-Ras by Abl allosterically enhanced the binding of H-Ras
to its effector protein Raf. Serine/threonine phosphorylation of
Ras proteins may also play important roles in their regulation.
For example, H-Ras phosphorylation by GSK3β on threonine
residues 144 and 148 results in polyubiquitination and
proteasome-mediated degradation [22]. Protein kinase C–
dependent K-Ras4B phosphorylation was also found on
Ser181, which is located in the C-terminal hypervariable
polybasic region. Phosphorylation of K-Ras S181 induces
rapid translocation of the protein from the plasma membrane
to internal membranes, including the endoplasmic reticulum
and the mitochondrial membrane. Since phosphorylated K-
Ras interacts with Bcl-xL at the outer mitochondrial mem-
brane, K-Ras was implicated in cell death regulation [23,
24]. Recently, a poorly characterized serine/threonine kinase,
STK19, was identified as a novel activator of N-Ras [25].
STK19 phosphorylates N-Ras on the evolutionarily conserved
Ser89 in the protein’s α3-helix. Ser89 phosphorylation facil-
itates interactions between N-Ras and its downstream effec-
tors, e.g., B-Raf and PI3Kα, resulting in increased activation
of the MAP kinase cascade and the PI3K pathway. The po-
tential therapeutic effect of a STK19 inhibitor was successful-
ly tested in a melanoma model. It was shown that the selective
STK19 inhibitor ZT-12-037 (1a) markedly inhibited N-Ras–
driven melanoma development and growth both in vitro and
in animals [25] (Fig. 2).
The cooperation between Src and Ras in cell growth regu-
lation and tumorigenesis has been known for years. For ex-
ample, both Ras and Src are downstream members of epider-
mal growth factor (EGF) signaling [8, 9, 26]. Viral Src can
phosphorylate the adaptor protein Shc, which then recruits
Grb2/SOS complexes for Ras activation at the plasma mem-
brane [27]. Ras has been shown to be essential for v-Src–
stimulated cell transformation of human gallbladder epithelial
cells or invasive pancreatic ductal adenocarcinoma [28, 29].
p120RasGAP was identified as an effector of c-Src activation
by oncogenic Ras [30]. Furthermore, Src cooperates with mu-
tant Ras in tumourigenesis through the JNK and PI3K path-
ways [31], although no direct relationship between Src and
Ras has been identified in this process. Recent studies from
the laboratory of Michel Ohh demonstrated that Src tyrosine
kinase directly phosphorylates Ras on tyrosine 32 within the
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Fig. 1 Model for SOS-dependent Ras activation upon growth factor
stimulation. In quiescent cells, SOS is maintained in an inactive
conformation by the autoinhibitory function of its PH-DH domains. In
response to growth factor treatment, SOS is initially recruited to the
membrane via at least two independent sites: a proline-rich Grb2-
binding site and its lipid-binding PH domain. Contact between the PH
domain and phospholipids induces conformational changes that allow
allosteric Ras binding, which is followed by processive substrate Ras
activation. SOS remains bound at the plasma membrane for minutes
and is then subjected to endocytosis. As SOS ultimately seems to
appear in perinuclear vesicles, it is likely that SOS translocation to the
membrane in response to growth factor stimulation is a one-way process.
CDC25, CDC25 homology domain; DH, Dbl homology domain; EGFR,
epidermal growth factor receptor; HD, histone-like domain; PH,
Pleckstrin homology domain; PA, phosphatidic acid; PR, proline-rich
domain; REM, Ras exchanger motif
Fig. 2 Phosphorylation site of
Ras proteins. Schematic
representation of the
phosphorylation sites discussed in
this review. GSK3β, glycogen
synthase kinase 3β; PKA, protein
kinase A; PKC, protein kinase C;
STK19, serine/threonine-protein
kinase 19
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switch I region [32]. Interestingly, Src can bind to and phos-
phorylate Ras, but only the GTP-bound form; therefore, it is
highly likely that Src distinguishes between the different con-
formations of Ras and can bind only to the activated G protein.
Ras tyrosine 32 phosphorylation has two important effects on
Ras signaling: phosphorylation inhibits the binding of the ef-
fector protein Raf while increases the binding of the GAP
protein leading to enhancedGTP hydrolysis [32]. Both chang-
es facilitate a conformational shift in Ras that inactivates the
Ras cycle.
Real-time nuclear magnetic resonance experiments have
shown that Src kinase phosphorylates not only Tyr32 in K-
Ras but also Tyr64 [33]. This activity is particularly interest-
ing since Tyr32 is located in the switch I region (aa 30-38)
while Tyr64 is positioned in the switch II sequence of K-Ras
(aa 59-76). These regions of Ras undergo conformational
changes when GDP is exchanged for GTP. In the GTP-
bound state, Tyr35 and Gly60 form hydrogen bonds with
the γ-phosphate and lock the switch I and II regions in the
active conformations [17]. Both the switch I and II regions are
implicated in the binding of effectors and GAP proteins. After
GTP hydrolysis, the γ-phosphate is released and both switch
regions return to the flexible conformation in the GDP-bound
state [17]. Considering the important roles of the switch re-
gions in Ras regulation, it is not surprising that Tyr32 and
Tyr64 phosphorylation markedly alters the conformation of
the switch I and II regions, negatively influencing every step
of the Ras cycle [33]. As such, K-Ras tyrosine phosphoryla-
tion significantly reduces the associated GEF and GAP activ-
ities and impairs binding of the Raf effector molecule [33].
The crystal structure of nucleotide-free Ras in complex
with the catalytic domain of SOS revealed that SOS induces
conformational changes in the switch I and II regions of Ras
[34]. Mutagenesis of residues at the switch II-SOS interface
showed that the primary contact residue is Tyr64, which was
buried in a hydrophobic pocket of SOS [35]. Interestingly, the
switch I region of Ras is also involved in the interaction with
SOS. Mutagenic analysis revealed that Tyr32 and Tyr40 play
fundamental roles in this contact. Mutation of these residues
resulted in an increase in the intrinsic rate of nucleotide ex-
change and decreased the binding of Ras to SOS [35]. These
findings largely explain why Tyr32 and Tyr64 phosphoryla-
tion in Ras, resulting in the incorporation of phosphate groups
at the contact sites of Ras and SOS, impairs GEF activity.
1.3 Ras activation by the SHP2 phosphoprotein
phosphatase
SH2 domain-containing protein tyrosine phosphatase 2
(SHP2), encoded by PTPN11, is associated with a number
of malignant conditions, including breast cancer, leukemia,
lung cancer, liver cancer, gastric cancer, and other cancer
types [36]. Germline-activating mutations in the PTPN11
gene cause Noonan syndrome, whereas somatic mutations
result in LEOPARD syndrome and childhood leukemia [36].
The protein phosphatase contains two SH2 domains, a PTP
catalytic domain and a C-terminal tail. The crystal structure of
the SHP2 tyrosine phosphatase has revealed how its catalytic
activity is regulated by its two SH2 domains. In the absence of
a tyrosine-phosphorylated–binding partner, SHP2 is kept in an
autoinhibited conformation by intramolecular interactions be-
tween the N-terminal SH2 domain and the phosphatase do-
main. However, in response to growth factor or cytokine stim-
ulation, binding of specific phosphotyrosine proteins to the N-
terminal SH2 domain releases the autoinhibition and activates
SHP2. Recognition of bisphosphorylated ligands by the tan-
dem SH2 domains is an integral element of the activation. The
C-terminal SH2 domain contributes binding energy and de-
fines specificity, but it does not have a direct role in activation
[36, 37].
In 2007, PTPN11 (the SHP2-encoding gene) was identified
as the first proto-oncogene that encodes a tyrosine phospha-
tase [38]. Although phosphatases are generally thought to be
negative regulators of signaling pathways involving protein
kinases, several lines of evidence suggest that SHP2 promotes
growth factor- and cytokine-induced Ras activation [39];
therefore, SHP2 has long been considered as a potential ther-
apeutic target in cancer treatment. It was demonstrated that
SHP2 inhibition blocks signaling from receptor tyrosine ki-
nases (e.g., the EGF receptor) to theMEK-ERK pathway [40].
SHP2 inhibition seemed lethal to cells that are driven by acti-
vated tyrosine kinases, and it was implicated in intrinsic and
acquired resistance to targeted cancer drugs [40]. Other data
demonstrated that pharmacological SHP2 inhibition is an ef-
fective therapeutic approach for cancer treatment. A selective
and orally bioavailable small-molecule SHP2 inhibitor,
SHP099, can block the Ras-Erk signaling pathway activated
by mutant receptor tyrosine kinases [41]. Interestingly,
SHP099 binding to the interface of the N-terminal SH2 do-
main and the tyrosine phosphatase domain stabilizes SHP2 in
the autoinhibited confirmation [41]. SHP2 inhibition alone
had very little or no effect on proliferation in non-small-cell
lung cancer (NSCLCs) cell lines; however, a combination of
SHP2 and MEK inhibitors showed marked synergy in K-
RAS-mutant NSCLC cells and in animal models [42, 43].
Finally, studies in which SHP2 was targeted with the small
allosteric inhibitor RMC-4550 demonstrated that it can be an
effective target in B-Raf mutant cancer cell lines. It was pro-
posed that the mechanism of the inhibitory effect involves
disruption of SOS-mediated Ras GTP loading [44].
Although several promising SHP2 inhibitors for use in
cancer therapy have been described in the last decade, the
precise mechanism by which SHP2 promotes Ras activation
remains fundamentally unclear. Bunda et al. identified for the
first time that SHP2 preferentially binds to and dephosphory-
la tes PTyr32 Ras [45] . They showed that SHP2
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dephosphorylates wild-type and mutant Ras, and the activities
of SHP2 and Ras were elevated in mouse and human glioblas-
toma multiforme cell lines. In addition, SHP2 inhibition facil-
itated phosphorylation of wild-type and oncogenic Ras,
resulting in inactivation of Ras and its downstream signaling
[45]. The above findings suggest the existence of another lay-
er of Ras regulation that might fine-tune the classical GEF/
GAP-mediated Ras cycle. In response to, for example, EGF
stimulation, Src tyrosine kinase is activated at the plasma
membrane where it preferentially phosphorylates GTP-
bound Ras in which the Tyr32 hydroxyl-group is rotated in
the optimal position for phosphorylation [32]. Tyrosine phos-
phorylation negatively regulates Ras, even in its GTP-bound
state, and blocks the Ras cycle. Release from this inhibition
can be achieved via the action of SHP2 phosphatase, which
dephosphorylates Ras protein (Fig. 3). What is the rationale
behind this regulation in terms of cancer treatment? Ras mu-
tations lead to decreased intrinsic Ras GTPase activity and/or
impaired binding of GAP protein to Ras, both of which lead to
sustained and elevated Ras activation. Mutant GTP-bound
Ras acts as a driver that contributes to the pathogenesis of
several cancer types. For many decades, Ras was thought to
be an “undruggable” cancer target, since no drug against Ras
had been approved by authorities [46]. The discovery that
SHP2 can dephosphorylate even mutant GTP-bound Ras in
tumor cells and release Ras from its inactive state establishes
SHP2 as a novel drug target that could be effective in Ras-
driven human cancer.
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Fig. 3 Proposed model of the
phosphorylation-dependent Ras
GTPase cycle. Normal Ras
signaling: EGF receptor
stimulation leads to simultaneous
activation of the SOS exchange
factor and Src tyrosine kinase.
GTP-bound Ras is a substrate of
Src, which phosphorylates Ras on
tyrosine 32 and tyrosine 64,
resulting in Ras inactivation.
Release from this inhibition can
be achieved via the action of
SHP2 phosphatase, which
dephosphorylates Ras protein.
Mutant Ras signaling: oncogenic
mutations activate Ras via a
defect in its ability to hydrolyze
GTP, thus locking Ras in a GTP-
bound state. Src phosphorylates
the constitutively active Ras, thus
leading to its inactivation. SHP2
dephosphorylates Ras allowing
downstream signaling. Therefore,
SHP2 is a novel drug target that
might be effective in Ras-driven
human cancer
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